MedTrace Logo

The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab: The TezEx Study

NCT06666504 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-10-30

No results posted yet for this study

Summary

Tezepelumab is a treatment that is approved by NICE (National Institute for Health and Care Excellence, https://www.nice.org.uk/) for patients with severe asthma, that remains poorly controlled despite high dose inhaled glucocorticosteroid medication.

The goal of this observational study is to learn why some patients with severe asthma continue to have asthma flare ups despite being on tezepelumab.

Conditions

Interventions

OTHER

Combined Retrospective and Prospective Data Analysis

Collection of both retrospective and prospective data all ready available for participant

Sponsors & Collaborators

Principal Investigators

  • David Jackson, PhD · Guys & St Thomas' NHS Foundation Trust

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-12-30
Completion
2026-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06666504 on ClinicalTrials.gov